» Articles » PMID: 22915585

Soluble Prion Protein Inhibits Amyloid-β (Aβ) Fibrillization and Toxicity

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2012 Aug 24
PMID 22915585
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

The pathogenesis of Alzheimer disease appears to be strongly linked to the aggregation of amyloid-β (Aβ) peptide and, especially, formation of soluble Aβ1-42 oligomers. It was recently demonstrated that the cellular prion protein, PrP(C), binds with high affinity to these oligomers, acting as a putative receptor that mediates at least some of their neurotoxic effects. Here we show that the soluble (i.e. glycophosphatidylinositol anchor-free) prion protein and its N-terminal fragment have a strong effect on the aggregation pathway of Aβ1-42, inhibiting its assembly into amyloid fibrils. Furthermore, the prion protein prevents formation of spherical oligomers that normally occur during Aβ fibrillogenesis, acting as a potent inhibitor of Aβ1-42 toxicity as assessed in experiments with neuronal cell culture. These findings may provide a molecular level foundation to explain the reported protective action of the physiologically released N-terminal N1 fragment of PrP(C) against Aβ neurotoxicity. They also suggest a novel approach to pharmacological intervention in Alzheimer disease.

Citing Articles

A Comprehensive Review on Preclinical Alzheimer's Disease Models: Evaluating their Clinical Relevance.

Kushwaha V, Kumar Sahu K Curr Pharm Biotechnol. 2024; 26(2):186-207.

PMID: 39161136 DOI: 10.2174/0113892010331845240802073645.


Cleavage site-directed antibodies reveal the prion protein in humans is shed by ADAM10 at Y226 and associates with misfolded protein deposits in neurodegenerative diseases.

Song F, Kovac V, Mohammadi B, Littau J, Scharfenberg F, Matamoros Angles A Acta Neuropathol. 2024; 148(1):2.

PMID: 38980441 PMC: 11233397. DOI: 10.1007/s00401-024-02763-5.


Imaging Amyloid-β Membrane Interactions: Ion-Channel Pores and Lipid-Bilayer Permeability in Alzheimer's Disease.

Viles J Angew Chem Weinheim Bergstr Ger. 2024; 135(25):e202215785.

PMID: 38515735 PMC: 10952214. DOI: 10.1002/ange.202215785.


Imaging Amyloid-β Membrane Interactions: Ion-Channel Pores and Lipid-Bilayer Permeability in Alzheimer's Disease.

Viles J Angew Chem Int Ed Engl. 2023; 62(25):e202215785.

PMID: 36876912 PMC: 10953358. DOI: 10.1002/anie.202215785.


Cellular prion protein offers neuroprotection in astrocytes submitted to amyloid β oligomer toxicity.

Marques C, Gomes R, Pedron T, Batista B, Cerchiaro G Mol Cell Biochem. 2022; 478(8):1847-1865.

PMID: 36576715 DOI: 10.1007/s11010-022-04631-w.


References
1.
Lu X, Wintrode P, Surewicz W . Beta-sheet core of human prion protein amyloid fibrils as determined by hydrogen/deuterium exchange. Proc Natl Acad Sci U S A. 2007; 104(5):1510-5. PMC: 1785245. DOI: 10.1073/pnas.0608447104. View

2.
Roychaudhuri R, Yang M, Hoshi M, Teplow D . Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem. 2008; 284(8):4749-53. PMC: 3837440. DOI: 10.1074/jbc.R800036200. View

3.
Guillot-Sestier M, Sunyach C, Druon C, Scarzello S, Checler F . The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. J Biol Chem. 2009; 284(51):35973-86. PMC: 2791025. DOI: 10.1074/jbc.M109.051086. View

4.
Vincent B, Paitel E, Saftig P, Frobert Y, Hartmann D, De Strooper B . The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J Biol Chem. 2001; 276(41):37743-6. DOI: 10.1074/jbc.M105677200. View

5.
Morillas M, Swietnicki W, Gambetti P, Surewicz W . Membrane environment alters the conformational structure of the recombinant human prion protein. J Biol Chem. 1999; 274(52):36859-65. DOI: 10.1074/jbc.274.52.36859. View